The ATM increase is a distress signal — the company burned through its PIPE cash and is now tapping the ATM at a deeply depressed price. With zero revenue, unresolved clinical hold, and a going concern, any rally into ATM selling should be faded. Watch for further ATM updates and potential reverse split announcement to maintain Nasdaq listing.
Price Chart
Executive Summary
Traws Pharma filed a 424B5 prospectus supplement to increase the ATM offering capacity by up to $3.1M, bringing total potential ATM sales to ~$10.8M. This comes on top of a prior S-3 resale registration creating 237% overhang, a Q1 2026 earnings report showing zero revenue, a $7.1M net loss, and a going concern audit opinion. The ATM increase signals desperate cash needs while the stock trades near $1.62, just above penny stock territory.
Key Facts
- ATM capacity increased by up to $3,128,399 to a total of ~$10.8M of potential sales under the Citizens JMP Securities ATM agreement.
- 3,607,270 shares have already been sold for ~$7.71M under the prior ATM program.
- Q1 2026 reported zero revenue and a $7.1M net loss ($-0.53/share); cash dropped to $3.1M before the April PIPE.
- An S-3 resale shelf filed 14 days prior registers 35.9M shares (237% of shares outstanding) for selling stockholders with no proceeds to the company.
- Audit report includes a going concern opinion, and the FDA clinical hold on the lead TXM program remains unresolved.
- Stock closed at $1.62 on May 20, 2026, near the low end of its 52-week range.
- Non-affiliate public float was ~$32.2M based on 14.5M shares at $2.22 (March 23 close).
Financial Impact
Up to $3.1M in additional ATM dilution, totaling ~$10.8M potential; combined with the 35.9M-share S-3 resale overhang (237% of float).
Risk Factors
- Massive dilution from both ATM sales and the S-3 resale shelf.
- Zero revenue and unsustainable cash burn — potential bankruptcy or restructuring.
- FDA clinical hold on lead TXM program threatens pipeline value.
- Stock price below $1 risks Nasdaq non-compliance delisting.
- Going concern audit opinion indicates material uncertainty about survival.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001104659-26-065444 |
| Document: 0001104659-26-065444-index-headers.html | 0001104659-26-065444 |
| Document: 0001104659-26-065444-index.html | 0001104659-26-065444 |
| Document: 0001104659-26-065444.txt | 0001104659-26-065444 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | S-1 | $0.3500 | awaiting T+20 | — | $0.3700 (−5.71%) |
Oct 23, 2026 4d ago | 8-K | $0.3411 | awaiting T+20 | — | $0.3700 (−8.47%) |
Oct 20, 2026 7d ago | DEFA14A | $0.3760 | awaiting T+20 | — | $0.3700 (−1.60%) |
Oct 20, 2026 7d ago | DEF 14A | $0.3760 | awaiting T+20 | — | $0.3700 (+1.60%) |
Aug 14, 2026 10w ago | Press Release | $0.5400 $0.5200 | ▲ +3.70% | ▲ +2.18% | $0.3700 (+31.48%) |
Jul 10, 2026 15w ago | 8-K | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3700 (+45.98%) |
Jul 10, 2026 15w ago | 424B5 | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3700 (+45.98%) |
Jul 10, 2026 15w ago | EFFECT | $0.7600 $0.5320 | ▲ +30.00% | ▲ +32.43% | $0.3700 (+51.32%) |
Jul 9, 2026 15w ago | 8-K | $0.7600 $0.5320 | ▼ −30.00% | ▼ −32.43% | $0.3700 (−51.32%) |
Jul 1, 2026 16w ago | S-3 | $0.7677 $0.4411 | ▼ −42.54% | ▼ −42.13% | $0.3700 (−51.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers